Background.-Migraine is a chronic neurologic disease that can be associated with significant migraine-related impact, disability, and burden. Patient-reported outcome measures (PRO) are included in clinical trials of migraine interventions to capture treatment effects from a patient perspective. Clinical and regulatory guidelines also encourage use of PROs in trials. The Migraine Functional Impact Questionnaire (MFIQ) is a novel PRO measure, assessing the impact of migraine on Physical Function (PF), Usual Activities (UA), Social Function (SF), and Emotional Function (EF), in the past 7 days. Scientific methods recommended to meet the requirements of the U.S. Food and Drug Administration were followed, to ensure that the MFIQ content included outcomes that were relevant to adults with migraine and were clinically relevant, specifically to evaluate preventive treatments for migraine.
INTRODUCTION
Migraine is a chronic neurologic disease that is known to cause debilitating and disruptive physical symptoms that often impact social, emotional, academic, occupational, and personal aspects of life.
1-5 U.S. Headache Consortium Guidelines for the Pharmacological Management of Migraine Headache in the Primary Care Setting recommend that treatments for migraine should improve function and reduce disability, in addition to reducing the frequency, intensity, and duration of attacks and improving responsiveness of attacks to treatment. 6 Guidelines for the management and evaluation of migraine treatments also emphasize the importance of collecting data on the impact of migraine on functioning (ie, reducing migraine-related disability, burden, and impact), and suggest using patient-reported outcome (PRO) instruments to support clinical endpoints in migraine clinical trials. 7, 8 Guidelines recommend that PRO instruments should include concepts relevant to patients (using evidence based on patient input) and have robust measurement properties in the target population. 9 Several PRO instruments exist that measure migraine-related disability, burden, and impact, such as the Headache Impact Test (HIT-6 TM ), 10 Migraine Disability Assessment (MIDAS), 11 and Migraine-Specific
Quality-of-Life Questionnaire (MSQ). 12 However, a review showed that these instruments had limited coverage of some of the multifaceted impacts of migraine on functioning, that are relevant to adults, particularly the key facets of physical functioning: acts (things that an individual can do independent of context or purpose) and tasks (things people do in daily life in a specific context, with purpose). 13 Existing instruments also have gaps in FDA-recommended development steps required by regulatory guidelines issued in 2009 that highlight the importance of content validity and patient input. 1, 9, 14 The existing instruments also utilize longer recall periods that capture the patient's overall assessment of their condition but not recent episodes. 15 For example, the HIT-6 TM , MIDAS, and MSQ have recall periods of 4 weeks or longer. In contrast, a daily diary such as the Migraine Physical Function Impact Diary (MPFID), 16, 17 which captures the daily impact of migraine, can ideally track the day-to-day fluctuations that can occur during the various phases of a migraine episode. A recall period longer than 7 days may potentially limit the accuracy of recall about these dayto-day variations and impacts of migraine and related symptoms. The Migraine Functional Impact Questionnaire (MFIQ) was developed to address the gaps in existing PROs, specifically by providing a method to capture the comprehensive impact of migraine in the past 7 days on Physical Function (PF); Usual Activities (UA); Social Function (SF), and Emotional Function (EF). A 7-day recall period was selected to capture the variability of migraine symptoms and impacts, while being less burdensome than a daily assessment and reducing potential recall bias associated with longer recall intervals. The initial MFIQ items were generated based on concept elicitation interviews with patients, and content validity was further confirmed via cognitive interviews. 1, 14 Clinical experts in migraine also provided input in the development and finalization of the MFIQ. Items use a 5-point response scale. For items relating to concepts/activity that may not be relevant to the subject during a particular week (eg, "ability to take care of your family)," a "does not apply" response option can be used. The MFIQ was developed for use in clinical trials and other research settings. It has recently been used in trials evaluating an investigational migraine preventive therapy 18 and a prospective observational survey of migraine preventive treatment. 19, 20 The MFIQ has also been translated into 20 languages following best practice recommendations for linguistic validation of PRO instruments. 14 The MFIQ has also been noted in the recently published "Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults" as a PRO tool that can be used to support secondary endpoints in clinical trials of preventive treatments for migraine. 21 Strong measurement properties of a PRO instrument are crucial for the interpretability and generalizability of the constructs being measured. 22 The primary objective of this study was to finalize the content of the MFIQ and conduct a psychometric evaluation of measurement properties using data from an observational study.
METHODS
Study Design and Population.-A prospective, observational study was conducted (in 2014-2016) with adults 18 to 65 years of age diagnosed with migraine, who could speak and read English. Eligibility criteria aimed to mirror criteria typically used for a migraine clinical trial of preventive therapies, to capture a similar patient population. The study enrolled adults with episodic migraine (≥4 and ≤14 migraine headache days per month, in each of 3 months prior to screening) and chronic migraine (≥15 headache days per month, of which ≥8 were migraine days, in each of the 3 months prior to screening), consistent with ICHD-III 2013 criteria for EM and CM. The study excluded individuals participating in a clinical trial within 45 days of screening; older than 50 at time of migraine onset; people with cluster headache or hemiplegic migraine headache, or with comorbid conditions known to cause substantial pain (fibromyalgia, chronic pelvic pain syndrome); EM with migraine attacks lasting over 72 hours in duration in the 3 months prior to screening; CM with continuous pain; opioid use for greater than 6 days per month during the 3 months prior to screening; individuals unable to differentiate migraine from other headache; and anyone with a cognitive impairment that would preclude participation (in the opinion of the investigator). Diagnoses were confirmed by clinicians (nurses, doctors, and other healthcare professionals) or via chart review and patient self-report of number of migraine days during screening.
The study included 2 cohorts. Cohort 1 (followed for 4 weeks) was used to inform item reduction, scoring, and cross-sectional properties (reliability and validity) and included subjects who were receiving usual standard of care migraine treatment, either taking a preventive migraine medication or no preventive treatment (acute treatments were permitted). Cohort 2 (followed for 16 weeks) was used to examine responsiveness to change included subjects starting a new preventive medication and/or increasing the dose of a current preventive medication.
Note: Data from this observational study were also used to explore the properties of a daily assessment of the impact of migraine, specifically on physical function using the MPFID. Information about the MPFID is reported in Hareendran et al 2017 16 and Kawata, Hsieh, et al 2017.
Subjects were recruited via 35 clinical sites in geographically diverse areas of the United States, including general practice facilities and neurology/ headache centers. The sample size for Cohort 1 was determined based on a minimum requirement of at least 5-10 subjects per item or 100-200 subjects 23, 24 for item evaluation and factor analyses. The sample size for Cohort 2 was estimated for evaluating responsiveness based on the results of 2 pivotal trials of topiramate 25 which evaluated the change in average area under the curve (AUC) of the MSQ. A sample size of at least 100 subjects was required for Cohort 2, to include an adequate number of subjects for a preliminary evaluation of longitudinal properties to discriminate responder and nonresponder groups. A type I error rate of P < .05 was assumed, and a 2-sided 2-sample t-test was used for the power calculation. All study procedures were approved by a central Institutional Review Board (Ethical & Independent Review Services, Corte Madera, CA, 14020-01), and subjects provided written informed consent. Subjects attended 2 clinic visits: Cohort 1 at Day 1 (study start) and Week 4, and Cohort 2 at Day 1 (study start) and Week 16, and responded to questions on an electronic device each day between study visits. Subjects completed a headache diary on the electronic device that collected data about headache and associated symptoms, medications taken for acute migraine pain and symptoms, and the level of migraine interference with daily activities (average score, categorized as none [0] , mild [1] [2] [3] , moderate [4] [5] [6] , severe [7] [8] [9] [10] ). PRO instruments were also completed on the electronic device throughout the study at specific time points ( Table 1 illustrates the schedule of instrument completion in each cohort and scores generated from these instruments. Item analyses were conducted on the 31-item draft MFIQ (v.1), and psychometric analyses were conducted with the subset of items retained in the final MFIQ (v.2; 26 items). Version 1.0 and the final version of the MFIQ representing impacts of migraine in 4 areas of functioning is described in Table 2 .
Statistical Analyses.-Statistical analyses were conducted in 3 stages and in accordance with best practices for instrument development/psychometric evaluation 23 and recommendations outlined in the FDA PRO Guidance document. 9 In Stage 1, an interim sample (n = 259) was used to evaluate the performance of items in MFIQ v.1 at study start (Day 1) to confirm content validity, inform item reduction, identify domain structure, and develop a scoring algorithm utilizing data collected at study start from Cohorts 1 and 2. Following completion of item reduction and scoring in Stage 1, the measurement properties of MFIQ v.2 were evaluated using the full study sample. In Stage 2 (n = 553), the cross-sectional measurement properties of the domains identified in Stage 1 were assessed, based on data collected at the end of Week 4 from Cohorts 1 and 2. In Stage 3 (n = 267), responsiveness of MFIQ v.2 scores were assessed with the Cohort 2 sample using analysis of covariance (ANCOVA) models to compare score change from Weeks 4 or 8 to Week 16. Time points used to evaluate change over time in Cohort 2 were adjusted based on the assessment schedule (see Table 1 ).
Analyses were conducted using all available data and missing clinical and PRO data were not imputed. All statistical tests (unless otherwise noted) used a significance level of P < .05 (2-sided) and did not adjust for multiplicity. All statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC), with the exceptions of factor analyses conducted using Mplus 7.11 29 and item response theory (IRT) analyses performed using IRTPRO 2.1.
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Stage 1: Item Analysis, Item Reduction, and Scoring.-Item-level descriptive statistics were generated for the MFIQ v.1. A priori criteria for flagging items for potential item reduction included: large floor or ceiling effects (>30% at minimum or maximum response option); high (r > 0.80) or low (r < 0.20) item-to-item correlations; low factor loadings (<0.40) or items that loaded on more than 1 factor (>0.40); and misfit within the domain in IRT analysis (item chi-square P < .01 30 or based on Bonferroni-adjusted criteria).
Item selection and scoring were informed by exploratory factor analysis (EFA) and IRT analysis using the graded response model. IRT was used as a secondary method to assess item performance and unidimensionality of the MFIQ domains in conjunction with item-level evaluation and factor analysis. Confirmatory factor analysis (CFA) was used to confirm the factor structure derived using EFA. EFA and CFA models were conducted using weighted least squares mean and variance adjusted (WLSMV) estimation and goodness of fit was assessed based on comparative fit index (CFI; ≥0.90), 31 root mean square error of approximation (RMSEA; <0.08 with narrow 90% confidence interval), 32 and standardized root mean residual (SRMR; <0.10) for EFA or weighted root mean square residual (WRMR; close to or ≤1.0) 33 for CFA. Internal consistency reliability (the extent to which individual items in a scale measure a common underlying concept) was evaluated at study start (Day 1) and Week 4 using Cronbach's alpha >0.70 as indicative of acceptable reliability. 34 Test-retest reliability (ability to generate reproducible results) of MFIQ scores was assessed among subjects who had stable status (based on PGIC "no change in migraine" at Week 4) from Day 1 to Week 4 using intraclass correlation coefficients (ICC). An ICC >0.70 indicates good test-retest reliability, between 0.4 and 0.7 indicates moderate reliability, and <0.4 indicates low reliability.
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Construct validity was evaluated with data from Week 4 using Spearman rank-order correlations. Correlations between MFIQ scores and other indicators of conceptually related constructs based on clinical and PRO assessments that would be expected to show associations were examined to support convergent validity. For example, moderate correlations were expected between MFIQ scores and frequency of migraine days and headache days; moderate to large correlations were expected between MFIQ PF and PROMIS-PF scores, between MFIQ UA and SF scores with MSQ Role Function-Restrictive (RF-R) and Role Function-Preventive (RF-P) scores, and between MFIQ EF and MSQ EF scores. Strength of a correlation was evaluated based on standards proposed by Hinkle and colleagues: small <0.3; moderate 0.3-0.6; large >0.6. Known-groups validity (the extent to which scores show expected differences among groups of subjects differing by a relevant clinical marker 36 was assessed using data from Week 4 based on groups known to be clinically different based on headache variables and other PRO scores: number of weekly migraine days and headache days (categorized as 0 days, 1-2 days, ≥3 days), level of migraine interference with daily activities, HIT-6 severity of headache impact score, and MSQ domains (median scores). Mean MFIQ scores and standard deviations (SDs) were calculated for each severity/disease status category and ANCOVA was used to compare mean differences between groups, controlling for age and sex. Stage 3: Responsiveness.-In Stage 3, the ability of the MFIQ v.2 to detect change (responsiveness) from Week 4 or Week 8 to Week 16 (n = 267) was assessed. ANCOVA compared MFIQ score changes over time (controlling for age and sex), and baseline MFIQ scores between groups differing by responder status. A responder was defined as a subject showing change on clinical variables (≥50% reduction in monthly migraine days or monthly headache days) and PRO anchor variables (≥50% reduction in migraine interference with daily activities; improved on the PGIC; change of at least 5 points on HIT-6; change of at least 5 points on MSQ RF-R and RF-P domains, and change of at least 8 points on MSQ EF domain).
RESULTS

Patient
Characteristics.-The full study sample used in Stage 2 to evaluate psychometric properties of the MFIQ included 569 subjects: 323 (56.8%) with EM and ) †Check all that apply; percentages may sum to more than 100%. ‡Clinician-reported; diagnoses of migraine without aura and migraine with aura are not mutually exclusive. Min-Max = minimum-maximum; SD = standard deviation. 246 (43.2%) with CM. The mean age was 39.9 years (SD = 12.0; range: 18-65), and 87.2% (n = 496) were female, 80.8% (n = 460) were white, and most (70.1%; n = 399) were employed full-or part-time. Clinicians categorized 64.5% (n = 367) of subjects as having migraine without aura. The most common current migraine preventive medications were topiramate (34.3%; n = 195) and tricyclic antidepressants (eg, amitriptyline, nortriptyline, protriptyline) (17.6%; n = 100). Approximately one-third of subjects were currently using simple analgesics (nonsteroidal antiinflammatory drugs [NSAIDs], acetaminophen) (29.0%; n = 165) as acute treatment for migraine. A total of 103 subjects (18.1%) were not using any migraine medication (Table 3) .
PRO instrument scores of the sample at study entry are presented in Table 4 . A majority of subjects (≥75%) had HIT-6 TM scores (>59) suggesting "severe" headache impact, and mean MSQ scores (<65) that indicated presence of limitations in the areas of daily social and work-related activities. The average PROMIS-PF T-score was 49.2, suggesting overall physical functioning comparable with the U.S. general population norm of 50.
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Sample characteristics for the Stage 1 interim sample and the Cohort 2 sample used in Stage 3 to evaluate responsiveness were largely similar to the full study sample. Cohort 2 subjects were starting new preventative medications for migraines or increasing the dose of a current preventative medication upon enrollment into the study. The most common medication in this group was topiramate. Overall, 89% of expected daily diary entries were completed by patients. EFA was performed on the MFIQ v.1 data at study start (Day 1) to evaluate the domain structure of the items. One-, 2-, 3-, and 4-factor models were evaluated. EFA results suggested good fit for the 1-factor (CFI = 0.953, SRMR = 0.060; RMSEA = 0.123), 2-factor (CFI = 0.969, SRMR = 0.043, RMSEA = 0.104), and 3-factor (CFI = 0.976, SRMR = 0.035, RMSEA = 0.094) models. However, the 4-factor model showed the best fit to the data, as supported by CFI = 0.982 and SRMR = 0.027. In addition, RMSEA (0.086) was only slightly above the conventional cut-off of <0.08 for acceptable fit. Item loadings ranged from 0.391 to 0.892 across the 4 factors. Strong correlations between the factors (0.551-0.560) suggested that these factors also reflected an overarching concept of migraine impact.
IRT analyses supported unidimensionality of the 4 MFIQ domains, and suggested that items generally functioned in an orderly way within the scales and contributed to the measurement of their respective domains. Among physical function items, ability to move inside home (item 3) showed evidence of misfit (P = .003). When it was omitted, all items had adequate fit (P ≥ .022). Otherwise, fit statistics did not identify any evidence of substantial item misfit. Usual activities (P ≥ .040), social function (P ≥ .094), and emotional function items (P ≥ .037) all showed adequate fit within their respective domains. The results of item-level analyses based on a priori criteria were considered along with results from previous qualitative work with patients and input from clinical experts to inform decisions on item selection. The items dropped all had high correlations with other similar items, indicating redundancy, and the most conceptually relevant items were selected in discussion with clinical experts. Five items were dropped, for a total of 26 items in the final MFIQ v.2 ( Table 2) . Good to moderate test-retest reliability was demonstrated among subjects who were stable (based on PGIC "no change in migraine" at Week 4) for MFIQ scores from Day 1 to Week 4 (n = 235). All domain scores and the global UA item score demonstrated good to moderate test-retest reliability (ICCs for PF = 0.57, UA = 0.63, SF = 0.65, EF = 0.71, and global UA = 0.47).
Convergent Validity.-All MFIQ domains had good convergent validity with measures assessing similar constructs (Table 5) . Moderate correlations were observed between the number of migraine days and each MFIQ domain score (PF r = 0.48; UA r = 0.48; SF r = 0.47; EF r = 0.48) and the global UA item score (r = 0.48). Moderate correlations were also observed between the number of headache days and each MFIQ domain score (PF r = 0.43; UA r = 0.41; SF r = 0.41; EF r = 0.46) and the global UA item score (r = 0.41). Moderate to large correlations were observed between MFIQ v.2 scores and the HIT-6™ score, MSQ RF-R, RF-P, and EF domain scores, and PROMIS-PF score (Table 5) .
Known-Groups Validity.-MFIQ v.2 domain scores discriminated between groups of subjects known to be clinically different among groups varying by number of migraine days and headache days (P < .001). A pattern was observed of higher MFIQ v.2 domain scores corresponding to groups with greater numbers of migraine days during the 4 weeks, indicating that higher impact was related to having more days with migraine (Fig. 1) . MFIQ domain scores also increased with greater impact of headache based on HIT-6™ (Fig. 2) . Differences in mean MFIQ UA, PF, SF, and EF scores and HIT-6™ groups were identified for all pairwise comparisons across domains, except for minimal/mild vs moderate levels of impact which had few subjects in these groups. MFIQ domain scores also differentiated by groups with varying impact on quality of life based on MSQ RF-R, RF-P, and EF domain scores (P < .0001 for all MFIQ domains and the global UA item).
All mean MFIQ domain scores increased with higher levels of patient-reported interference of migraine with daily activities. Nearly, all pairwise comparisons of the MFIQ UA, PF, SF, and EF scores and the global UA item with the conceptually similar migraine interference level were nominally significant (P < .001). (Table 6 ). Subjects in the study sample with at least 50% reduction in monthly migraine days from Week 4 to Week 16 had significantly more change over time in MFIQ scores than those with less than a 50% reduction, in all domains and the global item (P < .0001; mean differences by responder status ranged from −13.00 to −17.18; Fig. 3 ). Subjects with a reduction in monthly headache days (≥50%) also showed more improvement in MFIQ scores over time in all domains (P < .01) and for the global item. MFIQ change scores were greater for responders (vs nonresponders) based on at least 50% reduction in migraine interference with daily activities (all domains) (P < .01).
Large differences in change over time in MFIQ domain scores with change in PGIC and other PROs (HIT-6 TM and MSQ) also supported the ability of MFIQ to detect changes in migraine impact (P < .05). MFIQ domain change comparisons to PGIC responder groups were significant for Improved vs No Change and Improved vs Worsened (P < .001), but not for No Change vs Worsened, for all domains. The differences in change over time on the global item score was only significant for the Improved vs Worsened comparison (P < .01). Responders based on HIT-6 TM ( Fig. 4) , MSQ domains, and PROMIS-PF showed more improvement on the MFIQ in all domains and for the global UA item, compared with nonresponders (P < .001; Table 6 ).
DISCUSSION
The final 26-item MFIQ v.2 assesses migrainerelated functional impacts in 4 domains: physical function, usual activities, emotional function, and social function. The MFIQ was developed with input from patients and feedback from clinical experts and has demonstrated reliability and validity. As expected, the MFIQ was moderately correlated with clinical and PRO measures assessing related constructs. It is responsive to change over time in migraine frequency, interference with daily activities, and PRO assessments. The MFIQ offers comprehensive concept coverage of the impacts of migraine that are most relevant to adults with the condition over a 7-day recall period.
When evaluating interventions intended to treat frequent migraines, a migraine-specific measure such as the MFIQ may be preferred over measures that were developed to assess the impact of headaches in general. Unlike some other PRO measures like the MIDAS and HIT-6 TM , the MFIQ offers separate domain scores enabling evaluating changes in the impact of migraine on both acts and tasks related to functioning and activities. The measure is not limited to solely physical or role impacts, as social and emotional impacts are also captured by the items. However, it was not designed to measure absenteeism from work or other areas of life, so in this regard, it may capture slightly different concepts than measures such as MIDAS or Work Productivity and Activity Impairment Questionnaire (WPAI). 37 Changes in the frequency and level of difficulty on these psychosocial impacts can be measured by the MFIQ. A recall period of the past 7 days used in the MFIQ enables capture of the experiences of adults experiencing frequent migraines, without the potential risk of recall bias associated with longer recall periods. The instrument may also be sensitive to impact that is not directly related to a migraine day in individuals with less frequent migraines. MFIQ scores suggested that some impairment is present even in subjects with no migraine days during week 4. These impairments in the absence of migraine could potentially be prodrome or postdrome impacts experienced between migraine attacks. The MFIQ is able to capture the week-to-week variability that is an important aspect of the frequent and episodic nature of migraine 38 and naturally occurring fluctuations in the disease. Although some items in the MFIQ reference activities that may not Minimal/Mild Impact (≤55), n=33 Moderate Impact (56-59), n=50 Severe Impact (>59), n=162 HIT-6 Score:
Analysis of covariance (ANCOVA) models adjusted for age and sex; Scheffe test for multiple comparisons. * P<0.05 or lower for all pairwise comparisons between Minimal/Mild Impact (≤55) vs. Severe Impact (>59) and Moderate Impact (56-59) vs. Severe Impact (>59); Minimal/Mild Impact (≤55) vs. Moderate Impact (56-59) were not significant for MFIQ domains or global item (p>0.05). occur daily (ie, work or study-related activities), patients have stated that these impacts are relevant and important to their migraine experience. Therefore, for those items that describe concepts that may occur less frequently, the response scale includes a "does not apply" option that can be used in cases where the activity was not relevant to a respondent during a particular week. If the MFIQ is administered every week, it may be feasible to average across multiple time points (eg, 4 weeks of assessments) to generate scores that are representative across a longer duration. However, the psychometric properties of multi-week scores have not been evaluated and would require additional analyses to establish their reliability and validity. The MFIQ is being used as an outcome measure in clinical trials and observational research. It may also be a useful tool for integration into clinical practice. It could be used for initial and ongoing assessments in clinical contexts to monitor outcomes and to enhance communication between patients and healthcare professionals for the management of migraine.
Requests for copies of the instrument may be addressed to the corresponding author.
LIMITATIONS
This study had a few limitations of note. Inclusion of subjects from the Stage 1 sample in the Stage 2 analysis may impact results derived from the subsequent psychometric analyses. However, the total sample included 305 additional subjects beyond those included in the interim sample, so any impacts on the results are considered relatively minimal. The ancillary measures included in the observational study allowed evaluation of convergent validity, but not discriminant validity. Recruitment of the patient sample for the observational study was intentionally limited to match a typical clinical trial sample and was limited to U.S. English. Subjects had to have at least 4 headache days per month to be enrolled in the study, which may also limit generalizability of this sample to the general population of migraine patients. 
Change in MFIQ Score
Responders ( 50% reduction from baseline in Monthly Migraine Days), n=113
Non-responders (<50% reduction from baseline in Monthly Migraine Days), n=154
CONCLUSIONS
The MFIQ reflects the multifaceted impacts of migraine on functioning that are most relevant to adults with migraine. This study has demonstrated that the MFIQ has robust psychometric properties and is sensitive to change over time. MFIQ scores can be used to assess and track the impact of migraine, evaluate therapeutic targets, identify gaps for intervention, and enhance dialog between patients and healthcare providers about specific impacts of migraine that need to be addressed. It may also be used to evaluate real-world outcomes of interventions for migraine in research and clinical practice settings. Future analyses will be conducted to develop responder definitions for interpreting clinically meaningful within-subject change over time. 
Change in MFIQ Score
Responders ( 5-point reduction on HIT-6™), n=63 Non-responders (<5-point reduction on HIT-6™), n=207
